Filtered By:
Condition: Thrombocytopenia
Drug: Taxotere
This page shows you your search results in order of date.
Order by Relevance | Date
Total 54 results found since Jan 2013.
Posterior reversible encephalopathy syndrome triggered by FLOT (5-fluorouracil, oxaliplatin, docetaxel, and calcium levofolinate) chemotherapy and thrombocytopenia (docetaxel and cisplatin) chemotherapy
We describe the case of a middle-aged woman with gastric cancer. She was under treatment by fluorouracil, leucovorin, oxaliplatin, and docetaxel regimen and thrombocytopenia regimen after tumor progression, but developed unconsciousness, irritability, and headache shortly after initiation of treatment. Her magnetic resonance imaging in our hospital shows abnormal signals in bilateral frontal parietal occipital lobes with hyperintensities on T2-weighted magnetic resonance imaging and fluid-attenuated inversion recovery imaging, accompanied by the increased value of apparent diffusion coefficient. And T1-weighted images illu...
Source: Cancer Control - May 23, 2023 Category: Cancer & Oncology Authors: LinLin Xie Source Type: research
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
CONCLUSION: Platinum-based chemotherapy with BEV followed by BEV maintenance for platinum-sensitive recurrence during PARP inhibitor treatment was shown to be efficacious and safe. This combination should be further evaluated in larger randomized clinical trials.PMID:36854492 | DOI:10.21873/anticanres.16273
Source: Cancer Control - February 28, 2023 Category: Cancer & Oncology Authors: Marina Abe Tadahiro Shoji Yohei Chiba Eriko Takatori Yoshitaka Kaido Takayuki Nagasawa Masahiro Kagabu Fumiaki Takahashi Takeshi Aida Tsukasa Baba Source Type: research
Treatment outcomes with radium-223 in docetaxel-na ïve versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan
Medicine (Baltimore). 2023 Feb 3;102(5):e32671. doi: 10.1097/MD.0000000000032671.ABSTRACTWhile radium (Ra)-223 is among the multiple, known life-prolonging treatments in bone-predominant metastatic castration-resistant prostate cancer (mCRPC), optimal treatment sequencing has not been determined, particularly in the Asia-Pacific context. Hence, we aimed to compare treatment outcomes of docetaxel-naïve and post-docetaxel mCRPC patients undergoing Ra-223 therapy in Taiwan. Using a single-center retrospective cohort design, we reviewed records of adult patients receiving Ra-223 for bone-metastatic mCRPC from 2018 to 2021. Pa...
Source: Cancer Control - February 7, 2023 Category: Cancer & Oncology Authors: Ping-Chia Chiang Po-Hui Chiang I-Hsuan Alan Chen Yen-Ta Chen Hung-Jen Wang Yuan-Tso Cheng Chih-Hsiung Kang Chien-Hsu Chen Yi-Yang Liu Yu-Li Su Yen-Hao Chen Hao-Lun Luo Source Type: research
Polymorphisms in solute carrier genes (SLC19A1, SLCO1B1, and SLCO1B3) predicts survival and toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy
CONCLUSION: Our findings imply that Solute Carrier gene polymorphisms modulate the overall survival in lung cancer patients undergoing platin-based doublet chemotherapy, also these polymorphisms have a modifying impact on the associated adverse events/toxicity.PMID:35896189 | DOI:10.1111/jcpt.13748
Source: Clinical Lung Cancer - July 27, 2022 Category: Cancer & Oncology Authors: Parul Sharma Navneet Singh Siddharth Sharma Source Type: research
Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial
CONCLUSIONS: Neoadjuvant chemotherapy plus camrelizumab for locally advanced HNSCC showed high ORR, pCR, and MPR rates, with an acceptable safety profile. These data support further evaluation of neoadjuvant chemoimmunotherapy for the treatment of locally advanced HNSCC.PMID:35766967 | DOI:10.1158/1078-0432.CCR-22-0666
Source: Clinical Cancer Research - June 29, 2022 Category: Cancer & Oncology Authors: Zhanjie Zhang Bian Wu Gang Peng Guixiang Xiao Jing Huang Qian Ding Chengzhang Yang Xingao Xiong Hui Ma Liangliang Shi Jinsong Yang Xiaohua Hong Jielin Wei You Qin Chao Wan Yi Zhong Yan Zhou Xueyan Zhao Yangming Leng Tao Zhang Gang Wu Min Yao Xiaomeng Zhan Source Type: research
Adverse Event Profile for Nanoparticle Albumin-Bound Paclitaxel Compared With Solvent-Based Taxanes in Solid-Organ Tumors: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
CONCLUSION AND RELEVANCE: Nab-paclitaxel increased the risk of hematologic and non-hematologic AEs in general, but anaphylaxis was less common, and the recovery duration of neurotoxicity was shorter. Weekly administration of nab-paclitaxel at a lower dosage provided better tolerance.PMID:34963337 | DOI:10.1177/10600280211058385
Source: The Annals of Pharmacotherapy - December 29, 2021 Category: Drugs & Pharmacology Authors: Fei He Jiaxuan Liu Xin Shen Zijing Wang Qiao Li Guohui Li Source Type: research
Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with < sup > 177 < /sup > Lu-PSMA-617: A single center study
CONCLUSION: PRLT with 177Lu-PSMA is well-tolerated and effective in metastatic prostate cancer patients who have no other treatment options available. The novel prognostic markers found in this study (high platelet count, superscan pattern) were associated with poor overall survival.PMID:34526249 | DOI:10.1016/j.remnie.2021.05.005
Source: Molecular Medicine - September 16, 2021 Category: Molecular Biology Authors: Soroush Zarehparvar Moghadam Emran Askari Ghasemali Divband Sara Shakeri Kamran Aryana Source Type: research
Toxicity and efficacy of concurrent androgen deprivation therapy, pelvic radiotherapy, and radium-223 in patients with de-novo metastatic hormone sensitive prostate cancer
CONCLUSIONS: This is the first trial of combination ADT, radium-223 and EBRT to pelvis, post docetaxel. The combination was safe, with an efficacy signal. Multi-centre RCTs are warranted.PMID:34187853 | DOI:10.1158/1078-0432.CCR-21-0685
Source: Clinical Cancer Research - June 30, 2021 Category: Cancer & Oncology Authors: Philip G Turner Suneil Jain Aidan Cole Arthur Grey Darren Mitchell Kevin M Prise Alan R Hounsell Conor K McGarry Sandra Biggart Joe M O'Sullivan Source Type: research
